Parkinson Disease
Conditions
Brief summary
To evaluate the efficacy and safety of tenofovir disoproxil fumarate in the treatment of Parkinson's disease. The changes of motor symptoms and the occurrence of adverse reactions in early Parkinson's disease patients who took tenofovir disoproxil fumarate and did not take Tenofovir disoproxil fumarate at different time points were compared.
Interventions
DRUGTenofovir Disoproxil Fumarate
take tenofovir disoproxil fumarate 300mg/d
Sponsors
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* 1: Parkinson's disease: Hoehn Yahr= 1 to 2.5 2: MMSE score≥24
Exclusion criteria
* 1: essential tremor, stroke, epilepsy and other well-defined neurological disorders 2: Or have received deep brain stimulation and other brain surgery 3: Abnormal liver and kidney function 4: Infected with chronic hepatitis B or AIDS (HIV-1 infection) 5: Severe depression, schizophrenia, other psychiatric disorders or drug dependence 6: Other serious physical diseases such as heart, lung, liver, kidney disease, blood disease and malignant tumor 7: Pregnant or lactating women and seniors over 65 years of age 8: Allergy or other contraindications to the investigational drug
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| UPDRS III（Unified Parkinson's Disease Rating Scale part 3） | 1 month、3 month | score：0-132，higher scores mean a worse outcome |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Non-Motor Symptom Scale（NMSS） | 1 month、3 month | score：0-360，higher scores mean a worse outcome |
| creatinine(μmoI/L) | 1 month、3 month | blood biochemistry test，normal\<97μmoI/L |
Countries
China
Outcome results
None listed